Abstract: The present invention relates to stable liquid pharmaceutical formulations of cyclophosphamide comprising cyclophosphamide and at least one pharmaceutically acceptable excipient wherein moisture content of the liquid formulation is less than about 2.0% by weight. The invention further relates to stable liquid formulations of cyclophosphamide prepared by a process comprising a step of reducing the moisture content from cyclophosphamide or liquid compositions of cyclophosphamide or both. The invention further relate to method of using such stable liquid formulations of cyclophosphamide for parenteral administration either as ready-to-use or ready-to-dilute for treating various cancer disorders.

Abstract: The present invention relates to stable liquid pharmaceutical formulations of cyclophosphamide comprising cyclophosphamide and at least one pharmaceutically acceptable excipient wherein moisture content of the liquid formulation is less than about 2.0% by weight. The invention further relates to stable liquid formulations of cyclophosphamide prepared by a process comprising a step of reducing the moisture content from cyclophosphamide or liquid compositions of cyclophosphamide or both. The invention further relate to method of using such stable liquid formulations of cyclophosphamide for parenteral administration either as ready-to-use or ready-to-dilute for treating various cancer disorders.

Abstract: The present invention provides a stable, non-aqueous, ready-to-use parenteral composition comprising: carfilzomib or pharmaceutically acceptable salt thereof, acidifying agent, optionally a surfactant, one or more solvents or co-solvents.

Abstract: The present invention provides a stable, non-aqueous, ready-to-use parenteral composition comprising: carfilzomib or pharmaceutically acceptable salt thereof, acidifying agent, optionally a surfactant, one or more solvents or co-solvents.

Abstract: The present invention relates to a stable non-aqueous, ready to dilute liquid pharmaceutical composition comprising (i) melphalan or a pharmaceutically acceptable salt thereof and (ii) polyoxyethylene sorbitan fatty acid esters; wherein the weight ratio of melphalan to polyoxyethylene sorbitan fatty acid esters is from about 1:0.75 to about 1:20; wherein, composition comprising melphalan, at a concentration of about 50 mg/ml to about 150 mg/ml; wherein, when the composition is diluted to produce melphalan at a concentration of about 0.1 to about 3 mg/ml, is physically and chemically stable up to about 4 hours.

Abstract: The present invention relates to novel impurities of cyclophosphamide having structure V, VI or VII, stabilized form of these novel impurities, a process of preparing a stabilized form and isolating thereof. The invention also relates cyclophosphamide formulations which include cyclophosphamide, at least one pharmaceutically acceptable excipient, and a certain level of these impurities having structure V, VI or VII. The invention further relate to method of using such stable liquid formulations of cyclophosphamide for parenteral administration in treating various cancer disorders.

Abstract: The present invention relates to novel impurities of cyclophosphamide having structure V, VI or VII, stabilized form of these novel impurities, a process of preparing a stabilized form and isolating thereof. The invention also relates cyclophosphamide formulations which include cyclophosphamide, at least one pharmaceutically acceptable excipient, and a certain level of these impurities having structure V, VI or VII. The invention further relate to method of using such stable liquid formulations of cyclophosphamide for parenteral administration in treating various cancer disorders.

Abstract: The present invention provides a stable, non-aqueous, ready-to-use parenteral composition comprising: carfilzomib or pharmaceutically acceptable salt thereof, acidifying agent, optionally a surfactant, one or more solvents or co-solvents.

Abstract: The invention provides a process for preparing a sterile suspension comprising aripiprazole. More particularly, the invention provides the process for preparing the sterile suspension comprising aripiprazole, wherein said process involves in-process moist-heat sterilization of said suspension comprising aripiprazole. The in-process moist-heat sterilization is particularly efficient and economical process for the sterilization of aripiprazole formulations for parenteral administration, wherein the formulation obtained by said process have comparable physicochemical characteristics with the commercially available Ability Maintena® Injection.

Abstract: The presently disclosed subject matter relates to methods for quantifying the amount of N-methyl-2-pyrrolidone (NMP) in a sample. In one exemplary embodiment, a method for the quantification of N-methyl-2-pyrrolidone (NMP) in a sample includes introducing a sample that includes 1,3-butadiene and NMP, if any, into a gas chromatography system coupled to a nitrogen phosphorous detector to produce a first signal; and comparing the first signal to a second signal produced from a standard of a known NMP concentration, to quantify the amount of NMP in the sample, where the sample is not concentrated for NMP prior to the introduction of the sample into the gas chromatography system.

Abstract: Aspects of the present invention provide stable liquid ready-to-use injectable formulation of bortezomib or pharmaceutically acceptable salts thereof. Another aspect of the present invention provides processes for preparation of such stable liquid ready-to-use injectable formulation of bortezomib and methods of using such formulations for treating various types of cancers in mammals.

Abstract: The present invention relates to stable liquid pharmaceutical formulations of cyclophosphamide comprising cyclophosphamide and at least one pharmaceutically acceptable excipient wherein moisture content of the liquid formulation is less than about 2.0% by weight. The invention further relates to stable liquid formulations of cyclophosphamide prepared by a process comprising a step of reducing the moisture content from cyclophosphamide or liquid compositions of cyclophosphamide or both. The invention further relate to method of using such stable liquid formulations of cyclophosphamide for parenteral administration either as ready-to-use or ready-to-dilute for treating various cancer disorders.

Abstract: The present invention provides stable liquid pharmaceutical formulation of pemetrexed or pharmaceutically acceptable salts thereof comprises at least one stabilizing agent selected from the group consisting of sodium formaldehyde sulfoxylate, EDTA and derivatives and mixtures thereof.

Abstract: The invention relates to a process for the synthesis of spheroidal magnesium alkoxide having improved mechanical strength and narrow particle size distribution, the process comprising reacting magnesium metal, in the presence of iodine, with a mixture of alcohols by step-wise heating first in the range of 40° C. to 65° C. for a period of 2 hours and then in the range of 65° C. to 80° C. for a period of 1 hour, further by maintaining reaction temperature at 80° C. for a period of 6-10 hours, the vapors of the mixture produced during the reaction being condensed in an overhead condenser, hydrogen gas produced during the reaction being vented off and the mixture of alcohols left after the reaction being filtered and reused. The invention also relates to spheroidal magnesium alkoxide particles synthesized by the method, to the Ziegler natta procatalyst synthesized by using the alkoxide and to the polymer resin synthesized using the procatalyst.

Abstract: The invention relates to a process for the synthesis of spheroidal magnesium alkoxide having improved mechanical strength and narrow particle size distribution, the process comprising reacting magnesium metal, in the presence of iodine, with a mixture of alcohols by step-wise heating first in the range of 40° C. to 65° C. for a period of 2 hours and then in the range of 65° C. to 80° C. for a period of 1 hour, further by maintaining reaction temperature at 80° C. for a period of 6-10 hours, the vapours of the mixture produced during the reaction being condensed in an overhead condenser, hydrogen gas produced during the reaction being vented off and the mixture of alcohols left after the reaction being filtered and reused. The invention also relates to spheroidal magnesium alkoxide particles synthesized by the method, to the Ziegler natta procatalyst synthesized by using the alkoxide and to the polymer resin synthesised using the procatalyst.

Abstract: Levelling agents for use in zinc electroplating solutions are described comprising thallous ions or a combination of peptone and thiourea. The thallous ions are preferably added to a concentration of at least 1 mg/l and the peptone-thiourea combination added to a concentration of at least 100 mg/l peptone and 50 mg/l thiourea.